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Abstract: The wild pig population on Molokai, Hawaii, USA is a possible reservoir for bovine
tuberculosis, caused by Mycobacterium bovis, and has been implicated in decades past as the source of
disease for the island’s domestic cattle. Heat-inactivated vaccines have been effective for reducing
disease prevalence in wild boar in Spain and could prove useful for managing M. bovis in Molokai
wild pigs. We designed an experiment to test this vaccine in wild pigs of Molokai genetics. Fifteen
3–4-month-old pigs were orally administered 106–107 colony forming units (cfu) of heat-inactivated
M. bovis (Vaccinates; n = 8; 0.2 mL) or phosphate buffered saline (Controls; n = 7; 0.2 mL). Each dose
was administered in a 0.5 mL tube embedded in a fruit candy/cracked corn mix. Boosters were given
seven weeks post-prime in the same manner and dose. Nineteen weeks post-prime, pigs were orally
challenged with 1 × 106 cfu of virulent M. bovis. Twelve weeks post-challenge, pigs were euthanized
and necropsied, at which time 23 different tissues from the head, thorax, and abdomen were collected
and examined. Each tissue was assigned a lesion score. Ordinal lesion score data were analyzed using
non-parametric Wilcoxon Signed Rank test. Effect size was calculated using Cohen’s d. Four of eight
Vaccinates and four of seven Controls had gross and microscopic lesions, as well as culture-positive
tissues. Vaccinates had statistically lower lesion scores than Controls in the following areas: gross
thoracic lesion scores (p = 0.013 Cohen’s d = 0.33) and microscopic thoracic lesion scores (p = 0.002,
Cohen’s d = 0.39). There were no differences in head lesion scores alone, both gross and microscopic,
nor were there differences when comparing combined gross and microscopic head and thoracic lesion
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scores. These results are indicative that this vaccination protocol affords a modest degree of infection
containment with this vaccine in Molokai wild pigs.
Keywords: Sus scrofa; wild pig; feral swine; Mycobacterium bovis; Mycobacterium tuberculosis
Complex; tuberculosis; vaccination
1. Introduction
Animal tuberculosis (TB), caused primarily by Mycobacterium bovis, a member of the Mycobacterium
tuberculosis Complex (MTBC), is a globally significant disease that affects numerous livestock and
wildlife species, as well as humans. Due to implementation in the United States of a national bovine
tuberculosis eradication program over 100 years ago, TB prevalence has been reduced in cattle to less
than 0.005% of herds today [1,2]. However, the presence of TB in free-ranging wildlife populations
has impeded eradication efforts in the United States, as well as worldwide. In addition to the disease
being endemic in white-tailed deer (Odocoileus virginianus) in the northeastern part of the state of
Michigan, it is possible, but not established, that wild pigs (sometimes referred to as feral swine;
Sus scrofa) on the Hawaiian island of Molokai may maintain the infection as well. Mycobacterium
bovis-infected swine have periodically been detected on the island, and were thought to be the source
of spillover to livestock in previous decades [3,4]. An effective vaccine against TB would be useful for
managing M. bovis in the Molokai wild pig population, if the disease were determined to be endemic.
Vaccination of free-ranging wildlife is feasible and has been shown to be successful in several wildlife
species, including wild boar (Sus scrofa), red fox (Vulpes vulpes), and raccoon (Procyon lotor) [5–7].
Application of an orally-administered, heat-inactivated M. bovis vaccine to bovine tuberculosis-affected
wild boar populations in Spain appears to have helped in reducing disease prevalence [8]. In addition,
that vaccine preparation administered orally has shown some efficacy in protecting cattle and cervids,
as well as goats and wild boar parenterally [9–13]. Here, we describe the use of heat-inactivated




No clinical signs or adverse effects were observed in any of the animals during the entire length of
the experiment. All but one pig voluntarily consumed the bait after anesthesia recovery for prime
vaccination. The exception was a pig that only successfully chewed and swallowed the bait once it was
placed directly into its mouth.
2.2. Gross and Microscopic Lesion Scores
Four of eight Vaccinates and four of seven Controls had visible gross lesions. Table 1 summarizes
gross and microscopic lesion scores.
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Table 1. Individual animal gross lesion scores, microscopic lesion scores, and Mycobacterium bovis culture outcome in tissues collected at necropsy from Vaccinates and
Controls twelve weeks post-challenge with 104 colony forming units (cfu) of virulent M. bovis strain 06-4387. Vaccinates received two oral doses of approximately 107
cfu inactivated M. bovis at 19 and 12 weeks prior to challenge.
Tissue (Gross Lesion Scores/Microscopic Lesion Score/M. bovis Culture Outcome: +/-)









ID Caud2,3 Cran2,4 Card2,5 Acc6 Liver Spleen Kidney Mand2,7 Parotid2 Retro-pharyngeal2
Superf
Cerv2,8 Medias
9 Tracheo-bronch2,10 Hep11 Mes12 Tonsil
Vaccinates 18 21
C 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 1,3/2,3/+ 0/0/- 1,4/1,3/+ 0/0/- 0/0/- 0/0/+ 0/0/+ 0/0/- 0/0/-
D 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 4/3/+ 0/0/+ 0/0/- 0/0/- 0/2/+ 0/0/+ 0/0/- 0/0/-
E 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 1/3/- 0/1/+ 0/0/- 0/0/-
H 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/-
K 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/-
L 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/-
M 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 4/3/+ 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/-
N 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/-
Controls 36 33
A 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/-
B 0/1/+13 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 4/3,1/+ 0/0/- 0/1/- 0/0/- 0/0/- 0/2/- 0/0/- 0/0/- 0/0/-
F 0/0/- 0/0/- 5/3,3/+ 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/+ 4,3/3,3/+ 0/0/- 0/0/- 0/0/-
G 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/-
I 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 4/3/+ 0/0/- 0/0/- 0/0/- 0/0/- 0/2/- 0/0/- 0/0/- 0/0/-
J 0/0/- 0/0/- 5,5/2,3/+ 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 3,3/3/+ 0/0/- 0/0/- 0/0/-
O 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/- 0/0/-
1 Average lesion score based on examination of 23 tissues; 2 Bilateral tissues were collected and total score from both tissues reported here; 3 Caud, Caudal Lung Lobes; 4 Cran, Cranial
Lung Lobes; 5 Card, Cardiac Lung Lobes; 6 Acc, Accessory Lung Lobe; 7 Mand, Mandibular Lymph Nodes; 8 Superf Cerv, Superficial Cervical Lymph Nodes; 9 Medias, Mediastinal Lymph
Node; 10 Tracheo-bronch, Tracheobronchial Lymph Nodes; 11 Hep, Hepatic Lymph Node; 12 Mes, Mesenteric Lymph Node; 13 Shaded cells have at least one positive outcome.
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The total gross and microscopic lesion scores in Vaccinates were 18 and 21, respectively, while
Controls had total gross and microscopic lesion scores of 36 and 33, respectively. Although means were
not directly compared by statistical methods, mean gross and microscopic lesion scores associated
with head and thoracic regions are presented in Figure 1 for descriptive purposes. There was no
statistical difference and no effect between the treatment groups when taking into account combined
head and thoracic gross lesion scores (p = 0.357, Cohen’s d = 0.08). The results were similar for combined
microscopic lesion scores (p = 0.095, Cohen’s d = 0.14). In addition, there were no differences when
comparing head region gross and microscopic lesion scores (p = 0.22 and 0.630, respectively). Neither
head region group showed any effect size (d = 0.06 for gross and d = 0.13 for microscopic lesion
scores). However, when comparing only thoracic scores, both gross and microscopic lesion scores were
statistically lower in Vaccinates than in Controls (p = 0.013 and 0.002, respectively). Cohen’s d effect size
was small to medium for these two lesion score groups (d = 0.33 and 0.40, respectively). There were no
gross lesions visible in the abdominal region of either group, and only one microscopic lesion was
detected in the hepatic lymph node of a Vaccinate.
Pathogens 2020, 9, x FOR PEER REVIEW 2 of 9 
 
The total gross and microscopic lesion scores in Vaccinates were 18 and 21, respectively, while 
Controls had total gross and microscopic lesion scores of 36 and 33, respectively. Although means 
were not directly compared by stat stical methods, mean gro s and microscopic lesion scores 
associated with he d and thorac  regions are presented in Figure 1 for descriptive purposes. There 
was no statisti al difference and no effect between the t eatment groups when taking into cc un  
combined head and thoracic r s  lesion scores (p = 0.357, Cohen’s d = 0.08). The esult  wer  similar 
for combine  microscopic lesion scores (p = 0.095, Cohen’s d = 0.14). In addition, there were no 
diff rences when comparing head region gross and microscopic lesion scores (p = 0.22 and 0.630, 
respe tively). N ither head region group s owed any effect size (d = 0.06 for g oss and d = 0.13 for 
mi roscopic lesion sc res). However, when comparing only thor cic scores, both gross and 
microscopic lesion scores re statistically lower in Vaccinates than in Controls (p = 0.013 and 0.002, 
respectively). Coh n’s d ffect size was small to medium for these two lesion sc re groups (d = 0.33 
and 0.40, respectively). There were no gross lesions visible in the abdominal region of either group, 
and only one microscopic lesion was detected in the hepatic lymph node of a Va cinate   
 
 
Figure 1. Mean gross and microscopic tissue lesion scores in Vaccinates and Controls by region. 
Means presented are for descriptive purposes only. Tissues collected at necropsy from Vaccinates and 
Controls 12 weeks post-challenge with 106 colony forming units (cfu) virulent M. bovis strain 06-4387. 
Vaccinates received two oral doses of approximately 107 cfu inactivated M. bovis at 19 and 12 weeks 
prior to challenge. 
2.3. Culture 
Four of eight Vaccinates and four of seven Controls had tissues that were culture positive for M. 
bovis. Vaccinates had a total of ten tissues that were positive on culture, three of which were not 
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positive in any abdominal tissues. 
Figure 1. Mean gross and microscopic tissue lesion scores in Vaccinates and Controls by region.
Means pr sented are for des iptive purposes only. Tissues collected t necropsy from Vaccinates and
Control 12 weeks post-challenge with 106 colony forming uni s (cfu) vi ulent M. bovis strain 06-4387.
Vaccinates r ceived two oral doses of appr ximately 107 cfu inacti ated M. bovis at 19 a d 12 weeks
pr or to challenge.
2.3. Culture
Four of eight Vaccinates and four of seven Controls had tissues that were culture positive for
M. bovis. Vaccinates had a total of ten tissues that were positive on culture, three of which were not
associated with gross lesions or microscopic lesions, representing two animals. Control animals had a
total of eight positive tissues, one of which one was not associated with gross or microscopic lesions.
Three Vaccinates had culture positive hepatic lymph nodes, whereas no Controls were culture positive
in any abdominal tissues.
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3. Discussion
Oral vaccination and boost by heat-inactivated Mycobacterium bovis shows moderate efficacy
in controlling disease severity in wild pigs of Molokai genetics when experimentally infected with
virulent M. bovis nineteen weeks after prime and twelve weeks after boost vaccination. This is especially
evident when comparing the treatment groups in terms of gross and microscopic lesion scores of the
thoracic region, as the lungs and associated lymph nodes of the Vaccinates sustained statistically lower
lesion scores than did the Controls. Our observed outcomes are comparable to those produced in
controlled studies in wild boar, in which significant protection against disease was demonstrated in
animals vaccinated twice with inactivated M. bovis [13–15].
These results, although modest in effect, invite consideration of the vaccine having the ability
of reducing the occurrence of airborne transmission of M. bovis. As summarized by Naranjo et al. in
2008 [16], lesion development in wild pig populations can vary; some populations experiencing lesions
predominately in the head region, suggesting an oral route of infection, such as wild pigs in Australia in
decades past. Other populations, such as wild boar in Mediterranean Spain, sustain more generalized
disease, involving head and/or thorax, suggesting the possibility of multiple infection routes. We used
an oral inoculation method for this study, because we believe that route likely predominates in wild
pigs on Molokai. However, airborne transmission among pen mates may have occurred in our study
as well.
It is notable that three Controls and four Vaccinates did not sustain any lesions, nor were any of
their tissues culture positive for M. bovis. It may be that these animals were not successfully colonized
by the bacteria after administration of challenge material, or perhaps they were less susceptible to
infection than their cohorts were. In this study, we did not perform additional assays that would
indicate evidence of pathogen exposure, such as those that detect antibody development against M.
bovis antigens. We therefore we could not determine if the animals effectively responded to infection
and prevented colonization, or if no actual infection took place. Additional work is clearly needed to
further evaluate the susceptibility of Molokai-origin pigs to M. bovis infection.
It is interesting that, although not significant, Vaccinates did seem to have a higher rate of lesion
development in the lymphoid tissues of the head region than did the Controls. In addition, three
Vaccinates had positive cultures in hepatic lymph nodes, one of which also had a microscopic lesion,
representing the only evidence of abdominal region infection in any of the animals in this study. Further
studies exploring the pathogenesis of this strain of M. bovis in wild pigs from various geographic
origins need to be performed to more fully understand these potential differences in response to and
progression of infection. In line with these data, researchers in Spain have applied heat-inactivated M.
bovis in free-ranging wild boar piglets with apparent success in reducing prevalence of disease caused
by MTBC in vaccinated wild boar populations, compared to unvaccinated populations [8]. Should
further investigation produce evidence that M. bovis persists in wild pig populations on Molokai Island,
then consideration should be given to continuing research in the use of heat-inactivated M. bovis as
part of an integrated disease management plan.
Exploration of the feasibility of vaccination of wild pigs on Molokai Island against M. bovis
infection must emphasize the importance of obtaining a comprehensive dataset on this population.
Complete knowledge of the population size, distribution, behavior, habitat use, and disease status
and ecology is crucial to targeting and applying disease management strategies most effectively. In
addition, information on the disease status of other TB-susceptible species on the island must be
obtained. This information is essential for development of effective vaccine delivery systems as well as
developing metrics for measurement of vaccine success [17–19].
Future work specifically addressing vaccine performance should include additional controlled
experiments with larger sample sizes. In tight isolation environments, logistical issues often limit
our abilities to achieve desirable sample sizes, and more natural and minimally stressful conditions
for these types of studies. Future work should also involve exploration of duration and nature of
immunity, comparison with M. bovis BCG vaccination, and use of lower doses of challenge inocula, or
Pathogens 2020, 9, 199 6 of 9
a natural challenge model, to more closely represent transmission in the field. Again, up to date data
need to be collected in order to determine if MTBC is still present and being maintained in the wild
pig population of Molokai as well as in other wild animal populations on the island. If a reservoir
situation is verified and characterized, further evaluation of disease management tools and strategies
should be performed.
4. Materials and Methods
4.1. Animals
Fifteen 3–4-month-old pigs were used for this study. Animals were offspring of wild pigs of
Molokai, Hawaii, USA origin. The pigs were born at the United States Department of Agriculture,
Animal and Plant Health Inspection Service/Colorado State University (CSU) Wildlife Research Facility
(WRF), Fort Collins, Colorado, USA (40◦34′5” N, 105◦08′49” W; elevation approximately 1519 m). Pigs
were housed for the vaccination portion of the study in two outdoor 3 m × 13 m solid panel runs
with soil substrate, and were offered a commercial swine ration fed at 0.5 kg/animal/day and water ad
libitum. For M. bovis challenge, the animals were transferred to the CSU, Biosafety Level 3 Animal
Disease Laboratory (ADL), where they were housed in 3.7 m × 5.5 m rooms and were fed and watered
as described above. This study was approved by CSU Institutional Animal Care and Use Committee
(IACUC Protocol # 17-7486).
4.2. Vaccination
Heat-inactivated M. bovis strain (#1403, Neiker) was prepared by Neiker Tecnalia in Derio, Bizkaia,
Spain as previously described [14,20]. The oral vaccine was shipped at a concentration of approximately
1 × 107 colony forming units (cfu) killed M. bovis per 0.2 mL.
Vaccine was administered orally within a candy mixed with cracked corn and fruit drink powder
for flavoring. A 0.2 mL (1 × 107 cfu) volume of vaccine or phosphate buffered saline (PBS) was
pipetted into a 0.5 mL centrifuge tube. Each tube was embedded in a 2 cm bait made out of the fruit
candy/cracked corn mix bait.
Animals were randomly assigned with blocking for gender to two groups: Vaccinates (n = 8)
or Controls (n = 7). On Day 0, pigs were anesthetized with isoflurane gas (FlurisoTM, Vetone, Boise,
Idaho, USA) via mask, and identifying ear tags were administered to both ears. Following full recovery
from anesthesia in individual recovery boxes, a bait with either vaccine or PBS was placed inside the
recovery box and the pig was given time to eat the bait. Seven weeks after prime vaccination, each
pig was boosted in the same manner as for the initial vaccination, without the anesthesia component.
Animals were housed in mixed Vaccinate and Control groups until challenge.
4.3. Challenge
Stock of M. bovis, strain 06-4387, originally obtained from a wild pig on Molokai, was received
from the USDA APHIS Veterinary Services, National Veterinary Services Laboratory (NVSL), Ames,
IA, USA and inoculated onto Middlebrook 7H11 agar plates. Cultures were incubated at 37 ◦C for
17 days, at which time confluent bacterial lawns had developed. Plates were flooded with PBS and
bacteria were harvested with a swab. Those suspensions were sonicated briefly to break up clumps
and counted using a Petroff–Hausser chamber. The resulting titer was 2.3 × 109 bacteria/5 mL, and that
suspension was diluted 1:2300 in PBS to yield an inoculum with a concentration of 106/5 mL.
Fifteen weeks post-prime, all pigs were anesthetized with intramuscular (IM) midazolam,
medetomidine, and butorphanol (Wildlife Pharmaceuticals Inc., Windsor, Colorado, USA) at 0.03, 0.06,
and 0.03 mg/kg, respectively, for transportation to the ADL [21]. Animals were transported 0.2 km
in a stock trailer and placed into two rooms in the same mixed groups as at the WRF. Anesthesia
was reversed with atipamezole (Wildlife Pharmaceuticals Inc.) at 5 mg per 1 mg medetomidine
administered. Nineteen weeks post-prime, pigs were sedated as above and orally challenged with
Pathogens 2020, 9, 199 7 of 9
1 × 106 cfu virulent M. bovis in 5mL PBS as described by Ballesteros et al. (2009) [22]. Anesthesia was
reversed as described above.
4.4. Necropsy
Twelve weeks post-challenge, pigs were anesthetized with IM butorphanol, azaperone, and
medetomidine (BAMTM, Wildlife Pharmaceuticals Inc.) at 0.027 mL/kg (0.73 mg/kg butorphanol,
0.24 mg/kg azaperone, and 0.27 mg/kg medetomidine), and euthanized via captive bolt [21]. The
animals were necropsied and the following 23 tissues collected for gross examination, histopathology,
and culture: lung (caudal (2), cranial (2), cardiac (2), and accessory lobe (1)), liver, spleen, kidney,
mandibular lymph nodes (LN, 2), parotid LN (2), retropharyngeal LN (2), superficial cervical LN (2),
tracheobronchial LN, hepatic LN, mesenteric LN, ileocecal LN, and tonsil. Any non-target tissues
with apparent lesions were also collected. On gross examination, each tissue was assigned a lesion
score as described by Garrido and others [20]. On microscopic examination, tissues were graded as
follows: Grade 1: single or multiple small lesions, generally less than or equal to 1 mm, composed
predominantly of inflammatory cells (PMNs, macrophages, and rare giant cells) usually having little
or no central caseous necrosis and mineralization; Grade 2: single or multiple moderate-sized lesions,
generally 2–3 mm, composed of inflammatory cells with moderate central necrosis and mineralization;
and Grade 3: single or multiple large lesions, generally greater than or equal to 4 mm, containing
inflammatory cells and marked central caseous necrosis and mineralization. Tissues for culture were
placed in Whirl Pak® bags (Nasco, Fort Atkinson, Wisconsin, USA) and stored at −70 ◦C until shipment
to the NVSL for processing. Tissues for histopathology were placed in 10% formalin and sent to
NVSL for processing. Fixed tissues were embedded in paraffin, sectioned at 5 µm, and stained with
hematoxylin–eosin by use of standard procedures. Tissues with lesions compatible with tuberculosis
underwent auramine-acridine orange and modified Ziehl–Neelson staining procedures (New Fuchsin)
to detect the presence of acid-fast organisms.
4.5. Culture
Mycobacterial cultures were performed as previously described with some modifications [23].
Briefly, tissues were trimmed, homogenized in saline, and decontaminated with 4% NaOH for 10 min.
Once samples were neutralized with a commercial buffer (IMMY, Norman OK, USA), they were
centrifuged at 4600× g and the pellet was inoculated into both BACTEC MGIT media and 7H11
Middlebrook with 0.5% hemolyzed blood, 10% calf serum, 0.39% sodium pyruvate, and 0.025%
malachite green as additives. Media were incubated according to manufacturer’s recommendations,
and signal positive tubes were examined for the presence of acid-fast bacteria. If the media signaled
positive prior to 42 days and no acid-fast organisms were detected, they were incubated at 37 ◦C for
the full 42 days and screened by polymerase chain reaction (PCR) [20]. All PCR-positive MGIT media
was subcultured onto solid media, and suspicious colonies were identified as M. bovis by PCR [24].
4.6. Statistics
Individual (not summed) gross and microscopic lesion scores within the treatment groups were
compared using non-parametric Wilcoxon Signed Rank test (α = 0.05). Lesion scoring results in a set
of scaled ordinal values and as such must be analyzed using methods that recognize the quantitative
nature of the values but do not treat them as continuous numbers [25,26]. Although suitable parametric
methods can be employed to analyze ordinal data, they operate best with large sample sizes [25,26].
The two treatment groups were limited to seven and eight individuals and we felt the best method for
our dataset was non-parametric analysis. Data used for statistical analysis were comprised of all node
pair scores in both Control and Vaccinate animals, where at least one lesion was detected in either
treatment group. Nodes or node pairs where lesions were absent for both groups were not included
as there were no lesion score data to compare. Table 1 shows which nodes or node pairs had lesion
scores. We used a Cohen’s d test suitable for ordinal values to calculate effect size since sample size
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can confound resulting p-values [27,28]. All statistical analyses were carried out in R: A language and
environment for statistical computing (Accessed 16 October 2019 and 1 March 2020).
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